Well, this is getting to be a familiar story, and not a happy one for Aldeyra Therapeutics Aldeyra Therapeutics (ALDX) shareholders. The company's stock is in freefall, down a brutal 68%, after the U.S. Food and Drug Administration (FDA) said "not yet" for the third time to its experimental dry eye disease treatment, reproxalap.
The latest setback came in the form of a Complete Response Letter (CRL) regarding the drug's New Drug Application. For those keeping score at home, that's regulatory-speak for "application denied."
The FDA's Core Complaint: Where's the Proof?
The heart of the FDA's rejection is pretty straightforward: they don't think Aldeyra has proven its case. The CRL stated there is "a lack of substantial evidence consisting of adequate and well-controlled investigations."
In plainer English, the agency is saying the data Aldeyra submitted from its clinical trials isn't convincing enough. The letter indicated the company failed to provide substantial evidence demonstrating reproxalap's efficacy in those controlled studies, which raises "significant concerns about the reliability of positive findings." Ouch.
Interestingly, the FDA didn't outright demand that Aldeyra run another massive, expensive clinical trial this time around. Instead, the agency suggested the company should dig into why some of its trials didn't work out and try to figure out if there's a specific group of patients—a certain population—where the drug might actually be effective. It's a bit like the FDA saying, "Maybe this key works, but you're trying it on the wrong doors."
Aldeyra's CEO, Todd Brady, struck a determined tone in a statement, emphasizing the "urgency of working with the FDA to enable market access for reproxalap," which he views as a potential breakthrough. You have to admire the persistence, even in the face of a 68% stock drop.
The Silver Lining? A Long Cash Runway
If there's any good news for Aldeyra amidst this regulatory storm, it's that the company isn't about to run out of money. As of December 31, 2025, the company reported having $70 million in cash and equivalents. Management expects that stash to fund operations all the way into 2028. That's a crucial cushion that gives them time to figure out their next move without the immediate panic of a cash crunch.
A History of Regulatory Hurdles
This rejection is part of a frustrating pattern for Aldeyra. The company submitted this NDA back on June 16. The FDA accepted it for review a month later on July 16, 2025, classifying it as a "complete class 2 response" and setting a target decision date (the PDUFA date) for December 16. That date was later extended to March 16, 2026, which is when this latest shoe dropped.
Rewind to April 2025, and you'll find the second Complete Response Letter. At that time, the FDA said the application "failed to demonstrate efficacy in adequate and well-controlled studies" and explicitly stated that "at least one additional adequate and well-controlled study" should be conducted.
Go back even further to November 2023, and you hit the first rejection. That initial CRL also asked for at least one more symptom trial. So, in summary: Ask One, denied. Ask Two (a resubmission), denied. Ask Three (another resubmission), denied. It's a tough regulatory gauntlet.
ALDX Price Action: The market's verdict was swift and severe. Aldeyra Therapeutics shares were down 68.61% at $1.32 at the time of publication, hovering perilously close to its 52-week low of $1.13.
